HRG expression may predict clinical response to trastuzumab in breast cancer without HER2 amplification and can mediate acquired resistance to lapatinib.[97, 98] NRG-Beta1 mediates trastuzumab emtansine resistance and treatment with pertuzumab circumvents this issue.[99]. The gene discussed is ERBB2; the disease is breast carcinoma.